Akili (AKLI) said Tuesday its video game app, EndeavorOTC, has received a clearance from the US Food and Drug Administration as an over-the-counter treatment for adults with attention-deficit/hyperactivity disorder.
The company said EndeavorOTC is its second digital ADHD therapeutic to receive FDA authorization. EndeavorOTC is available in the US on the Apple App Store for iOS and the Google Play Store for Android mobile devices.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments